Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)
NCT 04091126 Brief Summary This study will evaluate the safety, pharmacokinetics,…
Read more arrow_forwardNCT 04091126 Brief Summary This study will evaluate the safety, pharmacokinetics,…
Read more arrow_forwardNCT 05317416 Brief Summary The purpose of this study is to…
Read more arrow_forwardInside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.